Healthscope Ltd falls 2.75% on news it may divest its Asian pathology

The Healthscope Ltd (ASX: HSO) share price has fallen by 2.75% on news that it may divest its Asian pathology business according to the AFR.

Healthscope is Australia’s second largest private hospital operator and could be one of the biggest winners from the expected rise in patients due to Australia’s ageing demographics.

However, there’s more to Healthscope’s business than just private hospitals in Australia. Healthscope also has a pathology business which operates in Malaysia, Singapore and Vietnam.

The AFR reports that UBS is helping Healthscope with part of the review to consider if Healthscope should sell its Asian pathology business.

Asian healthcare companies are supposedly interested and some interested suitors include Fullerton Healthcare and IHH Healthcare.

If Healthscope were to sell its Asian subsidiary it would hope for a selling price of around $200 million.

If the sale went ahead it’s expected that most of the funds would be redeployed into expanding the Australian private hospital business segment, which management see as the key source of future growth.

I actually think that Healthscope has a good long-term future thanks to its expansion plans and the ageing demographics that Australia faces. Healthscope’s model of running a joint public and private hospital, such as Northern Beaches Hospital in Sydney, could be successful in the future.

Foolish takeaway

Healthscope is currently trading at 19x FY18’s estimated earnings, which isn’t cheap. If Healthscope were to fall another 10% to 15% then I’d be interested in buying more shares but I’m going to hold off for now. I think the market crash presents better opportunities elsewhere.

For example, I think these top shares look like good value after today’s crash.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tristan Harrison owns shares of HEALTHSCPE DEF SET. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!